28.7% mean body weight reduction. Unprecedented in obesity medicine. A board-certified internist breaks down the TRIUMPH trial results, the triple agonist mechanism, and the realistic path to FDA approval.
By Dr. Teja V. Surapaneni, MD, MS • Board-Certified Internal Medicine (ABIM) • May 2026
If you’ve followed the GLP-1 weight loss space, you know the progression: semaglutide (Wegovy) produced approximately 15% weight loss in landmark trials. Tirzepatide (Zepbound) pushed that to 20–22%. Now Eli Lilly’s retatrutide is producing numbers that were unthinkable in obesity medicine just five years ago — up to 28.7% mean body weight reduction in early Phase 3 data.
Retatrutide (LY3437943) is a triple hormone receptor agonist — meaning it simultaneously activates three hormone pathways:
That third lever — glucagon agonism — is what makes retatrutide distinct from every approved weight loss medication available today. It’s not doing more of the same thing. It’s operating through a genuinely different third pathway.
The foundation was laid in a landmark Phase 2 trial published in the New England Journal of Medicine in August 2023 (Jastreboff et al., NEJM 2023;389:514–526). This was a double-blind, randomized, placebo-controlled trial in 338 adults with obesity or overweight without type 2 diabetes.
Mean weight loss at 48 weeks by dose:
| Dose | Mean Weight Loss at 48 Weeks |
|---|---|
| 1 mg | −8.7% |
| 4 mg | −17.1% |
| 8 mg | −22.8% |
| 12 mg | −24.2% |
| Placebo | −2.1% |
To put 24.2% in context: a 250-pound person would be expected to lose approximately 60 pounds on the 12 mg dose over 48 weeks.
Responder rates at 48 weeks (12 mg dose):
The cardiometabolic secondary endpoints were equally impressive: significant improvements in systolic and diastolic blood pressure, triglycerides, LDL cholesterol, total cholesterol, HbA1c, and fasting glucose.
A separate substudy published in Nature Medicine (2024) found that liver fat was reduced by up to 82% relative from baseline at 24 weeks. Non-alcoholic fatty liver disease (NAFLD/MASLD) affects an estimated 80–90% of individuals with obesity. The glucagon receptor component appears to drive direct hepatic fat oxidation — a mechanism that semaglutide and tirzepatide cannot match.
Eli Lilly’s Phase 3 program is called TRIUMPH — eight parallel trials evaluating retatrutide across obesity, type 2 diabetes, cardiovascular disease, osteoarthritis, sleep apnea, chronic back pain, and metabolic liver disease.
The first Phase 3 results were announced in December 2025 — positive across every primary and key secondary endpoint.
TRIUMPH-4 was a 68-week, randomized, double-blind, placebo-controlled trial in adults with obesity or overweight and knee osteoarthritis, without type 2 diabetes.
Key findings from TRIUMPH-4:
If TRIUMPH-1 and TRIUMPH-2 read out as expected, Lilly is projected to file an NDA with the FDA in Q4 2026, with a potential approval timeline of late 2027 to 2028.
| Medication | Mechanism | Max Mean Weight Loss | FDA Status |
|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 agonist | ~15% | Approved |
| Tirzepatide (Zepbound) | GLP-1 + GIP dual agonist | ~22% | Approved |
| Retatrutide | GLP-1 + GIP + Glucagon triple agonist | ~28.7% (Phase 3) | Investigational |
The step-up in efficacy at each generation has been consistent: adding GIP to GLP-1 (tirzepatide) improved weight loss by approximately 5–7 percentage points over semaglutide. Adding glucagon receptor agonism (retatrutide) appears to add another 5–7 percentage points over tirzepatide.
The safety data from Phase 2 and TRIUMPH-4 is reassuring, though Phase 3 completion will provide the full picture.
Most common side effects (consistent with the GLP-1 class):
These are dose-related, occur primarily during dose escalation, and are generally mild to moderate. A lower starting dose (2 mg rather than 4 mg) meaningfully reduced early gastrointestinal side effects in Phase 2.
The heart rate finding: Phase 2 data showed dose-dependent increases in heart rate that peaked at 24 weeks and declined thereafter. This is being monitored closely in Phase 3. Mild heart rate increases are seen with other GLP-1 and GIP/GLP-1 agents, but the magnitude in retatrutide warrants attention, particularly in patients with existing cardiac arrhythmias.
The standard GLP-1 class contraindications will likely apply: personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2), active pancreatitis, and severe gastrointestinal disease. The complete contraindication and warning profile will be defined by the FDA label at time of approval.
At YourMD Telehealth, our weight management program currently routes patients to FDA-approved branded GLP-1 medications — Wegovy® and Ozempic® through NovoCare, and Zepbound® and Mounjaro® through LillyDirect. This is deliberate: we are a physician-led practice, and we prescribe only medications that have completed full regulatory review and carry an FDA-approved label.
Retatrutide, if approved, would be a natural extension of this approach.
For patients who need more than tirzepatide can offer. If a patient has been on maximally tolerated tirzepatide for 12+ months and has plateaued at 15–18% weight loss but still has significant comorbidities — metabolic syndrome, fatty liver disease, orthopedic complications — retatrutide’s additional 7–10 percentage point effect could be clinically transformative.
For patients with fatty liver disease. The 82% relative reduction in liver fat seen in Phase 2 is extraordinary. NAFLD/MASLD is underdiagnosed and carries serious long-term consequences including cirrhosis and hepatocellular carcinoma. A weight loss medication that addresses hepatic fat directly — not just as a downstream consequence of weight loss — would change how we approach these patients.
For patients with obesity and osteoarthritis. TRIUMPH-4’s data is compelling. Knee pain as a barrier to physical activity creates a cycle that is very difficult to break with lifestyle alone. A medication that reduces both joint pain and body weight simultaneously addresses the loop at both ends.
For patients who need the highest efficacy from day one. Younger patients with severe obesity (BMI ≥ 40), patients facing orthopedic surgery who need specific weight loss targets, and patients with rapidly progressing metabolic disease may benefit from starting at the top of the efficacy ladder.
Retatrutide represents the most significant advance in obesity pharmacotherapy since tirzepatide. The Phase 2 data is exceptional. The first Phase 3 readout (TRIUMPH-4) confirmed those results hold in a larger, longer-duration trial. Seven more Phase 3 trials are expected to report throughout 2026.
This is not hype. The NEJM publication, the Nature Medicine liver substudy, and now TRIUMPH-4 form a consistent body of evidence that triple agonism — engaging GLP-1, GIP, and glucagon simultaneously — produces weight loss outcomes genuinely unprecedented in the history of obesity medicine.
The realistic timeline for FDA approval is late 2027 to 2028, contingent on TRIUMPH-1 and TRIUMPH-2 outcomes and the speed of the NDA review. Until then, the most effective approved option for weight loss remains tirzepatide (Zepbound).
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist from Eli Lilly that simultaneously activates GLP-1, GIP, and glucagon receptors. It is not yet FDA-approved. Phase 3 data showed up to 28.7% mean body weight reduction at 68 weeks.
Eli Lilly is expected to file an NDA with the FDA in Q4 2026, pending TRIUMPH-1 and TRIUMPH-2 Phase 3 results. The realistic approval timeline is late 2027 to 2028. Until approval, retatrutide cannot be legally prescribed in the United States.
Tirzepatide (Zepbound) produces approximately 22% mean body weight loss. Retatrutide's Phase 3 data showed up to 28.7% — roughly 6–7 additional percentage points. The difference is the addition of glucagon receptor agonism, which increases resting energy expenditure and drives direct hepatic fat oxidation.
No. Retatrutide is investigational and not available outside of clinical trials. YourMD does not prescribe investigational medications. If and when retatrutide receives FDA approval, we will evaluate it for our formulary and notify our patients.
Among FDA-approved options, tirzepatide (Zepbound) has the highest efficacy — up to 22.5% mean body weight loss in the SURMOUNT-1 trial. YourMD routes patients to Zepbound through LillyDirect. Start a free intake assessment to see if you qualify.
No credit card required. Physician review included.
Dr. Teja Surapaneni is a board-certified internal medicine physician (ABIM) licensed in Nevada, Washington, Oregon, and Wisconsin. YourMD Telehealth (United Medical Group, PLLC) is a physician-led DTC telehealth platform. This article is for educational purposes only and does not establish a physician-patient relationship. Retatrutide is investigational and not available for prescription. Always consult a qualified physician before starting any medical treatment.